Financial instruments - Collaboration and License Agreement (Details) |
12 Months Ended | |
|---|---|---|
|
Dec. 31, 2021
USD ($)
customer
|
Dec. 31, 2020
USD ($)
|
|
| Collaboration and License Agreement | ||
| Number of customers | customer | 3 | |
| Trade receivables | $ 752,000 | $ 139,000 |
| Amounts past due | 0 | |
| GlaxoSmithKline Intellectual Property Development Ltd | Astellas Collaboration Agreement | ||
| Collaboration and License Agreement | ||
| Impairment losses | $ 0 |
| X | ||||||||||
- Definition Number of customers. No definition available.
|
| X | ||||||||||
- Definition Amounts past due. No definition available.
|
| X | ||||||||||
- Definition Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|